Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending May 27, 2016. The report serves as a notification of corporate governance changes, specifically the appointment of a new Non-Executive Director to the Board.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a corporate announcement regarding board composition and does not contain financial performance data.
Material Changes
The primary material change disclosed is the appointment of Dr. Vivienne Cox, CBE, to the Board of Directors as a Non-Executive Director, effective July 1, 2016. She has also been appointed to the Corporate Responsibility Committee. The filing confirms that Dr. Cox is considered an independent Non-Executive Director in accordance with the UK Corporate Governance Code.
Guidance, Outlook, and Risks
The filing includes a standard cautionary statement regarding forward-looking statements, noting that actual results may differ materially from projections due to risks and uncertainties. These risks are referenced as being described under Item 3.D 'Risk factors' in the company's Annual Report on Form 20-F for 2015. No specific financial guidance or outlook is provided in this text.
Key Facts for Investor Verification
- New Appointment: Dr. Vivienne Cox joins the Board as an independent Non-Executive Director on July 1, 2016.
- Compensation Structure: Dr. Cox will receive annual fees of £85,000, with at least 25% paid in Ordinary Shares to align interests with shareholders.
- Background: Dr. Cox brings 28 years of experience from BP plc and current roles at Pearson plc, Stena International, and Vallourec.
- Committee Role: She is assigned to the Corporate Responsibility Committee.
- Board Composition: The filing lists the updated full Board composition effective July 1, 2016.